Newsroom
Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine
Inventvacc Biologicals is pleased to announce a recent publication of an original research article titled "Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine" in Vaccine journal. Link to publication:...
Vaccine to prevent deadly infections in Canada’s North reaches manufacturing milestone
InventVacc is pleased to contribute over four decades of vaccine manufacturing expertise to the manufacturing of the Hia vaccine.
Leading the way with Hia: Vaccine for the deadly infection gains traction
Licensed to InventVacc Biologicals Inc. for manufacturing in preparation for clinical trials
New vaccine targets pneumonia, blood poisoning, meningitis among children in Canada’s North
NRC recently gave the licence to manufacture the Type A vaccine to Vancouver-based InventVacc Biologicals Inc.